Pharmaceutical intermediates
Tazemetostat Hydrobromide Intermediates
9 pharmaceutical intermediates for Tazemetostat Hydrobromide. Indication: Follicular Lymphoma; Sarcoma.
About Tazemetostat Hydrobromide
- Originator
- Epizyme Inc
- Indication
- Follicular Lymphoma; Sarcoma
- Approved Date
- 01/23/2020
- NCE Patent
- 01/23/2025
- DS/DP
- 09/12/2031
Available intermediates
9 intermediates currently listed for Tazemetostat Hydrobromide. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 5-Bromo-2-methyl-3-nitrobenzoic acid | 107650-20-4 | / | / |
| Methyl 5-bromo-2-methyl-3-nitrobenzoate | 220514-28-3 | / | / |
| Methyl 3-amino-5-bromo-2-methylbenzoate | 1000342-11-9 | / | / |
| [1,1'-Biphenyl]-3-carboxylic acid, 5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, methyl ester | 1403258-99-0 | / | / |
| [1,1'-Biphenyl]-3-carboxylic acid, 5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)- | 1403259-00-6 | / | / |
| 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine | 364794-79-6 | / | / |
| 3-(aminomethyl)-4,6-dimethyl-1,2-dihydropyridin-2-one hydrochloride | 1173081-96-3 | / | / |
| Methyl 5-bromo-2-methyl-3-((tetrahydro-2H-pyran-4-yl)amino)benzoate | 1403257-49-7 | / | / |
| Methyl 5-bromo-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzoate | 1403257-79-3 | / | / |
我们能如何帮助您？
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →